Managing and Treating APDS2
At a Glance
APDS2 treatment is tailored to each person: immunoglobulin and antibiotics help prevent infections, while sirolimus or leniolisib can control immune overactivity. HSCT may offer a potential cure for selected severe cases but carries serious risks.
Treatment for APDS2 is not “one size fits all.” Because the disease affects the immune system in two opposite ways—under-activity (infections) and over-activity (swelling and autoimmunity)—your care team will likely use a multi-tiered approach tailored to your specific symptoms [1][2]. Not every patient requires every treatment.
Tier 1: The Foundation (Infection Prevention)
The first goal of treatment is to stop the cycle of recurrent infections that can lead to permanent lung damage [2]. These choices depend on infection history and specific antibody responses.
- Immunoglobulin Replacement Therapy (IRT): Most patients receive regular infusions of antibodies (IgG) to replace what their body cannot produce effectively [3]. This is associated with a significant reduction in the frequency and severity of infections, but is not automatically required for all [4].
- Prophylactic Antibiotics: Doctors may prescribe daily, low-dose antibiotics (such as trimethoprim-sulfamethoxazole) to prevent infections before they start [5][6].
- Vaccinations: Decisions about vaccines, especially live vaccines, must be individualized according to your immune function and current medications.
- Monitoring: Individualized pulmonary-function assessment and airway-clearance plans are utilized to watch for early signs of bronchiectasis (airway scarring). Chest CT scans are used when clinically indicated rather than on a routine schedule to minimize radiation [7].
Tier 2: Managing Over-Activity (mTOR Inhibitors)
When the immune system is too active—causing swollen lymph nodes, an enlarged spleen, or autoimmune issues—doctors may use a class of drugs called mTOR inhibitors, specifically sirolimus (also known as rapamycin) [8].
- How it Works: It helps “dial down” the hyperactive signaling pathway in your immune cells, often used off-label [9].
- Effectiveness: It is generally more effective at shrinking swollen lymph nodes and the spleen than it is at treating bowel inflammation or low blood counts [8].
- Monitoring: Because sirolimus can affect the kidneys, liver, and cholesterol levels, frequent blood tests are required to monitor drug levels and organ function [10][11].
Tier 3: Targeted Therapy (Leniolisib)
A significant breakthrough in APDS2 treatment is the development of leniolisib, a targeted “PI3K delta inhibitor.”
- Eligibility: It is currently approved for patients aged 12 and older in certain jurisdictions such as the US and EU (availability can differ by country) [12].
- Results: In clinical trials, leniolisib successfully reduced the size of lymph nodes and the spleen while increasing the number of healthy, “naive” B-cells [13]. Leniolisib controls disease manifestations rather than correcting the gene or eliminating the need for IRT.
- Long-term Data: In an observational extension study, patients taking the drug for several years reported fewer infections and, in some cases, were able to reduce their use of immunoglobulin replacement [14].
Tier 4: Curative Intent (HSCT)
Hematopoietic Stem Cell Transplant (HSCT) is currently the only treatment that can potentially cure APDS2 by replacing the “misprogrammed” immune system with healthy donor cells, but it carries substantial morbidity and mortality risks [15].
- Who is it for?: It is typically reserved for highly selected cases where medications are not working or where there is a high risk of organ failure or lymphoma [16][2].
- Outcomes: The 2-year overall survival rate in historical cohorts is approximately 86% [15]. Major trade-offs include graft-versus-host disease (GVHD), severe infection, and infertility.
- Specific Risks: APDS2 patients have a unique risk of graft failure (17% incidence in past cohorts), where the new immune system fails to take hold [15]. Retrospective research suggests an association between using mTOR inhibitors like rapamycin during the first year after transplant and a higher risk of graft failure (42% vs 9% without them), though transplant protocols are highly individualized [15].
Treatment Selection Guide
The following table outlines the general strategy doctors use to decide between these options:
| If you have… | The typical approach is… |
|---|---|
| Recurrent infections only | Individualized IRT and/or prophylactic antibiotics. |
| Severe swelling/autoimmunity | Consider Sirolimus (Rapamycin) or Leniolisib (if eligible). |
| Inadequate response to meds | Consider targeted clinical trials. |
| Refractory disease/malignancy | Early HSCT discussion for individualized counseling. |
Your medical team will work with you to balance the benefits of these treatments against their side effects, with the ultimate goal of protecting your long-term health and quality of life [1].
Common questions in this guide
What treatments are usually started first for APDS2?
When is leniolisib used for APDS2?
What should be monitored when a child takes sirolimus for APDS2?
When is a stem cell transplant considered for APDS2?
Does APDS2 treatment eliminate the need for immunoglobulin replacement?
Get notified when new evidence is published on immunodeficiency 132b.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
Spanish Consensus on the Diagnosis and Management of Patients With Activated PI3K Delta Syndrome (APDS).
Neth O, Alsina L, Rivière JG, et al.
Journal of investigational allergology & clinical immunology 2025; (35(2)):87-102 doi:10.18176/jiaci.1059.
PMID: 40028901 - 2
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Condliffe AM, Chandra A
Frontiers in immunology 2018; (9()):338 doi:10.3389/fimmu.2018.00338.
PMID: 29556229 - 3
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E, Neven B, Bruneau J, et al.
The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.
PMID: 27221134 - 4
Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys.
Ewertowska M, Grześk E, Urbańczyk A, et al.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2020; (16()):22 doi:10.1186/s13223-020-00420-6.
PMID: 32265996 - 5
Activated PI3Kδ syndrome - reviewing challenges in diagnosis and treatment.
Vanselow S, Wahn V, Schuetz C
Frontiers in immunology 2023; (14()):1208567 doi:10.3389/fimmu.2023.1208567.
PMID: 37600808 - 6
Listeria Meningitis as an Indication of Undiagnosed Primary Immune Deficiency, Activated Phosphoinositide 3-Kinase Delta Syndrome: A Case Report.
Canizci Erdemli P, Öcal Demir S, Bozkurt S, et al.
The Pediatric infectious disease journal 2025; (44(7)):672-675 doi:10.1097/INF.0000000000004737.
PMID: 39889727 - 7
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI, Chandra A, Bacon CM, et al.
The Journal of allergy and clinical immunology 2017; (139(2)):597-606.e4 doi:10.1016/j.jaci.2016.06.021.
PMID: 27555459 - 8
Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME, Abolhassani H, Aghamohammadi A, et al.
Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.
PMID: 29599784 - 9
Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Del Pino-Molina L, Torres Canizales JM, Rodríguez-Pena R, López-Granados E
Cytometry. Part B, Clinical cytometry 2021; (100(4)):460-466 doi:10.1002/cyto.b.21956.
PMID: 32961022 - 10
Sirolimus and Immunoglobulin Replacement Therapy in Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS): A Systematic Literature Review.
Hartog NL, Pisarczyk K, Samad M, et al.
Advances in therapy 2026; doi:10.1007/s12325-026-03833-8.
PMID: 42932134 - 11
Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase δ Syndrome 1: the First Case Series in Korea.
Kang JM, Kim SK, Kim D, et al.
Yonsei medical journal 2020; (61(6)):542-546 doi:10.3349/ymj.2020.61.6.542.
PMID: 32469178 - 12
Leniolisib: First Approval.
Duggan S, Al-Salama ZT
Drugs 2023; (83(10)):943-948 doi:10.1007/s40265-023-01895-4.
PMID: 37256490 - 13
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
Rao VK, Webster S, Šedivá A, et al.
Blood 2023; (141(9)):971-983 doi:10.1182/blood.2022018546.
PMID: 36399712 - 14
Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety.
Rao VK, Šedivá A, Dalm VASH, et al.
Journal of human immunity 2027; (3(1)) doi:10.70962/jhi.20260040.
PMID: 42873197 - 15
International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome.
Dimitrova D, Nademi Z, Maccari ME, et al.
The Journal of allergy and clinical immunology 2022; (149(1)):410-421.e7 doi:10.1016/j.jaci.2021.04.036.
PMID: 34033842 - 16
Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome in the Target Therapy Era.
Barzaghi F, Moratti M, Panza G, et al.
Journal of clinical immunology 2024; (45(1)):58.
PMID: 39714594
This page explains APDS2 treatment options for informational purposes only and does not constitute medical advice. Your immunology and transplant teams can help weigh medicines, monitoring, and HSCT risks for your specific situation.